123 related articles for article (PubMed ID: 9667250)
1. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
2. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J
Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659
[TBL] [Abstract][Full Text] [Related]
3. CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma.
Walewski J; Krzyzanowska JB; Kraszewska E; Lampka E; Romejko-Jarosińska J; Miśkiewicz Z; Meder J
Med Oncol; 2000 Aug; 17(3):195-202. PubMed ID: 10962530
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Ganjoo K; Hong F; Horning SJ; Gascoyne RD; Natkunam Y; Swinnen LJ; Habermann TM; Kahl BS; Advani RH
Leuk Lymphoma; 2014 Apr; 55(4):768-72. PubMed ID: 23786456
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks M;
Br J Haematol; 2009 Mar; 144(5):677-85. PubMed ID: 19055662
[TBL] [Abstract][Full Text] [Related]
6. Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.
Zuze T; Ellis GK; Kasonkanji E; Kaimila B; Nyasosela R; Nyirenda R; Tomoka T; Mulenga M; Chikasema M; Tewete B; Mtangwanika A; Chiyoyola S; Chimzimu F; Kampani C; Mhango W; Nicholas S; Randall C; Montgomery ND; Fedoriw G; Westmoreland KD; Painschab MS; Gopal S
Cancer Med; 2020 Jan; 9(1):77-83. PubMed ID: 31705618
[TBL] [Abstract][Full Text] [Related]
7. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Ghesquières H; Krzisch D; Nicolas-Virelizier E; Kanoun S; Gac AC; Guidez S; Touati M; Laribi K; Morschhauser F; Bonnet C; Waultier-Rascalou A; Orsini-Piocelle F; André M; Fournier M; Morand F; Berriolo-Riedinger A; Burroni B; Damotte D; Traverse-Glehen A; Quittet P; Casasnovas O
Blood; 2024 Mar; 143(11):983-995. PubMed ID: 37979133
[TBL] [Abstract][Full Text] [Related]
8. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
9. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Furman WL; McCarville B; Shulkin BL; Davidoff A; Krasin M; Hsu CW; Pan H; Wu J; Brennan R; Bishop MW; Helmig S; Stewart E; Navid F; Triplett B; Santana V; Santiago T; Hank JA; Gillies SD; Yu A; Sondel PM; Leung WH; Pappo A; Federico SM
J Clin Oncol; 2022 Feb; 40(4):335-344. PubMed ID: 34871104
[TBL] [Abstract][Full Text] [Related]
10.
Bascuas T; Moreno M; Grille S; Chabalgoity JA
Front Immunol; 2018; 9():7. PubMed ID: 29410666
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
12. Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.
Xu HN; Mir TA; Lee SC; Feng M; Farhad N; Choe R; Glickson JD; Li LZ
Adv Exp Med Biol; 2013; 789():243-249. PubMed ID: 23852501
[TBL] [Abstract][Full Text] [Related]
13. Current approaches to the treatment of non-Hodgkin's lymphoma.
Gisselbrecht C
Hematol Rep; 2011 Oct; 3(3s):e3. PubMed ID: 22586511
[TBL] [Abstract][Full Text] [Related]
14. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
Weycker D; Danel A; Marciniak A; Bendall K; Lipsitz M; Pettengell R
BMC Cancer; 2012 Aug; 12():362. PubMed ID: 22913768
[TBL] [Abstract][Full Text] [Related]
15. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Stuver R; Horwitz SM; Advani RH; Vose JM; Lee HJ; Mehta-Shah N; Zain JM; Haverkos B; Lechowicz MJ; Moskowitz AJ; Pham LQ; Leyden E; Ansell SM; Lunning MA
Br J Haematol; 2023 Aug; 202(3):525-529. PubMed ID: 37217196
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.
Wu H; Zhao C; Gu K; Jiao Y; Hao J; Sun G
Mol Clin Oncol; 2014 Sep; 2(5):695-700. PubMed ID: 25054032
[TBL] [Abstract][Full Text] [Related]
17. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
Iyer SP; Johnston PB; Barta SK
Blood Adv; 2024 Jan; 8(2):353-364. PubMed ID: 38029357
[TBL] [Abstract][Full Text] [Related]
18. Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.
Amadori D
Hematol Rep; 2011 Oct; 3(3s):e1. PubMed ID: 22586509
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.
Kaprio E; Prusila R; Tokola S; Kuusisto MEL; Jantunen E; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38164067
[TBL] [Abstract][Full Text] [Related]
20. Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
ELKasar AO; Hussien FZ; Abdel-Hamied HE; Saleh IG; Mahgoup EM; El-Arabey AA; Abd-Allah AR
Cancer Chemother Pharmacol; 2024 Feb; ():. PubMed ID: 38324036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
